GlassScriptPhysician profile
Jill Olmstead
NPI 1740276732
$24,286.07
in general payments reported to CMS, 2019-2025
30 companies · $5,940 in 2025
The $5,940 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,249 · 2022: $1,865 · 2023: $3,270 · 2024: $12K · 2025: $5,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,203 · Food and Beverage: $6,768 · Travel and Lodging: $4,622 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,202.50 |
| Food and Beverage | $6,767.74 |
| Travel and Lodging | $4,622.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,580.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $9,944.87 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,787.98 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $1,452.66 | 2022-2025 | Dupixent |
| Abbvie INC. | $1,126.32 | 2021-2025 | |
| Gilead Sciences, INC. | $783.64 | 2021-2025 | |
| Janssen Biotech, INC. | $617.32 | 2021-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $489.85 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $366.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $343.69 | 2021-2025 | Entyvio |
| Genzyme Corporation | $303.35 | 2022-2025 | |
| Celgene Corporation | $262.80 | 2021-2024 | Zeposia |
| Pfizer INC. | $223.88 | 2022-2025 | |
| Medtronic, INC. | $181.11 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $154.60 | 2025 | Iqirvo |
| Lucid Diagnostics INC. | $141.71 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $127.90 | 2021-2025 | Ocaliva |
| Organon LLC | $125.30 | 2021-2023 | Hadlima |
| Novo Nordisk INC | $120.39 | 2024 | |
| Janssen Scientific Affairs, LLC | $115.46 | 2021 | |
| Sage Therapeutics, LLC | $112.62 | 2023 | |
| Fresenius Kabi USA, LLC | $91.53 | 2023 | |
| Daiichi Sankyo INC. | $87.56 | 2021-2022 | |
| Lilly USA, LLC | $80.53 | 2024 | Omvoh |
| Qol Medical, LLC | $50.71 | 2023-2024 | Sucraid, Sucraid |
| Albireo Pharma, INC. | $49.58 | 2024 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.53 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $39.36 | 2021-2023 | Linzess |
| Azurity Pharmaceuticals, INC. | $25.81 | 2025 | Suflave |
| Alnylam Pharmaceuticals INC. | $23.32 | 2022 | |
| Intra-Sana Laboratories | $10.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Olmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.